Literature DB >> 16107893

Gatekeeper pathways and cellular background in the pathogenesis and therapy of AML.

J Cammenga1.   

Abstract

Acute myelogenous leukemia (AML) is characterized by the accumulation of immature cells due to disturbed differentiation and proliferation of the myeloid lineage. Genetic alterations affecting transcription factors and receptor tyrosine kinases have been identified in AML and causally linked to the disease. The goal of this review is to address the role of the different genetic alterations in self-renewal and proliferation and to discuss the cellular background in which these events occur during the pathogenesis of AML. Data from AML samples, clinical studies and mouse models for AML will be used to support the different theories regarding the leukemogenesis of AML. Finally, this review wants to highlight the implication of these findings for the therapy of AML.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16107893     DOI: 10.1038/sj.leu.2403894

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  4 in total

1.  Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors.

Authors:  Jessica K Altman; Antonella Sassano; Surinder Kaur; Heather Glaser; Barbara Kroczynska; Amanda J Redig; Suzanne Russo; Sharon Barr; Leonidas C Platanias
Journal:  Clin Cancer Res       Date:  2011-03-17       Impact factor: 12.531

Review 2.  Molecular mechanisms underlying deregulation of C/EBPalpha in acute myeloid leukemia.

Authors:  Kristian Reckzeh; Jörg Cammenga
Journal:  Int J Hematol       Date:  2010-04-27       Impact factor: 2.490

3.  Peripheral T cell lymphoma: new model + new insight.

Authors:  James C Mulloy
Journal:  J Exp Med       Date:  2010-05-03       Impact factor: 14.307

Review 4.  Targeting mTOR for the treatment of AML. New agents and new directions.

Authors:  Jessica K Altman; Antonella Sassano; Leonidas C Platanias
Journal:  Oncotarget       Date:  2011-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.